{
    "ASSERTIONS": {
        "id": 1,
        "context": "Chronic, accelerated, or blast phase",
        "description": "The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for adult patients with chronic, accelerated, or blast phase Philidelphia chromosome-positive (Ph+) CML with resistance or intolernace to prior therapy.",
        "disease": {
            "name": "Chronic Myelogenous Leukemia",
            "oncotree_code": "CML",
            "oncotree_term": "Chronic Myelogenous Leukemia"
        },
        "therapy_name": "Bosutinib",
        "therapy_type": "Targeted therapy",
        "clinical_significance": "sensitivity",
        "predictive_implication": "FDA-Approved",
        "favorable_prognosis": null,
        "created_on": "03/31/21",
        "last_updated": "2020-11-12",
        "submitted_by": "breardon@broadinstitute.org",
        "validated": true,
        "source_ids": 1,
        "variant": {
            "id": 1,
            "feature_type": "rearrangement",
            "gene1": "BCR",
            "gene2": "ABL1",
            "locus": null,
            "rearrangement_type": "Fusion",
            "feature": "BCR--ABL1 Fusion"
        }
    },
    "SOURCES": {
        "id": 1,
        "type": "FDA",
        "doi": null,
        "nct": "None",
        "pmid": "None",
        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203441s018lbl.pdf",
        "citation": "Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203441s018lbl.pdf. Revised June 2020. Accessed November 12, 2020."
    },
    "VARIANTS": {
        "id": 1,
        "feature_type": "rearrangement",
        "gene1": "BCR",
        "gene2": "ABL1",
        "locus": null,
        "rearrangement_type": "Fusion",
        "feature": "BCR--ABL1 Fusion"
    }
}